WebJan 10, 2024 · Earnings Estimate Revisions for Dyne Therapeutics, Inc. For the fiscal year ending December 2024, this company is expected to earn -$3.35 per share, which is a change of -14.3% from the year-ago ... WebApr 27, 2024 · DM1 Program Webcast . Following the presentations on May 14, 2024, Dyne plans to host a live webcast event at 4:00 p.m. ET to review the company’s DM1 program and preclinical data, and to ...
Press Releases Dyne Therapeutics, Inc.
WebOct 4, 2024 · Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, visits ... WebApr 3, 2024 · Dyne Therapeutics, a new biotechnology company pioneering targeted therapies for patients with serious muscle diseases, launched today with a $50 mill rawson neal psychiatric
Dyne Therapeutics Inc (DYN) Stock Price & News - Google …
WebNov 3, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary … WebDyne Therapeutics Information. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in ... WebSep 25, 2024 · CureDuchenne was an early investor in Dyne, whose FORCE™ platform and preclinical pipeline of modern oligonucleotide therapeutics, are aimed at transforming the lives of individuals living with ... rawson neal reviews